Mitophagy and Autophagy in Elderly Subjects

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

22 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-06-30

Study Completion Date

2016-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In recent years, evidence has shown that mitochondrial dysfunction plays an important role in the development of age-related muscle decline that may lead to frailty.

During aging, there is a progressive reduction in the cell's capacity to eliminate its dysfunctional elements by autophagy, as evidenced by the accumulation of oxidative damage and mutations in mitochondria and by the decrease in autophagic flux. In fact, it has been demonstrated that dysfunctional mitochondria can be specifically targeted for elimination by autophagy, a process that has been termed mitophagy.

A major challenge in the clinic today is in the lack of validated tools, including biomarkers, to assess the decline in mitochondrial health associated with an impairment in muscle function. In the present study, the investigators will employ a battery of established and exploratory tests (clinical, physiological and molecular) to assess in vivo mitochondrial function and more specifically, the levels of mitophagy and autophagy, in the muscle of healthy and pre-frail elderly.

It is anticipated that the results of this study will facilitate the rapid translation of interventions targeting mitophagy and autophagy for the improvement of muscle function.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Rejuvenation of Aged Muscle Stem Cells Through Exercise

NCT03473288

Autophagy and Apoptosis in Human Satellite Cells

WITHDRAWN NA

Nutritional Assessment in Mitochondrial Cytopathy

NCT02375438

Mitochondrial Diseases Mitochondrial Myopathies Mitochondrial Cytopathies

COMPLETED

Phase 1/2 Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)

NCT05747924

FSHD FSHD1 FSHD2 +24 more

ACTIVE_NOT_RECRUITING PHASE1/PHASE2

Low Residue Diet Study in Mitochondrial Disease

NCT03388528

Mitochondrial Diseases

COMPLETED NA

A Study to Evaluate a Skeletal-muscle Microbiopsy Technique With Dynamic Proteomic Measurement in Healthy Male Volunteers

NCT01962454

Cachexia

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Aging Frailty Mitophagy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Sedentary, Pre-frail

10 sedentary, pre-frail elderly, \>61 year of age

Muscle Biopsy

Intervention Type PROCEDURE

Muscle Biopsy

Active, Healthy

10 Active, healthy elderly, \>61 years of age

Muscle Biopsy

Intervention Type PROCEDURE

Muscle Biopsy

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Muscle Biopsy

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* for Active, Healthy subjects:

1. \>61 years of age, inclusive.
2. Healthy male subjects. Healthy status is defined by absence of evidence of any active or chronic disease following a detailed medical and surgical history, a complete physical examination including vital signs, 12-lead ECG, haematology, blood chemistry, and urinalysis.
3. Body mass index (BMI) between 15 and 32 kg/m2, inclusive.
4. Able to participate and willing to give written informed consent and to comply with the study restrictions.
5. Category 2 or 3 as assessed by the International Physical Activity Questionnaires (IPAQ). Activity level is ≥ 600 MET (metabolic equivalent unit) - minutes per week.
6. Normal physical performance: normal gait speed, i.e. a walking ≥ 0.8 m/s in the 4-m walking test.
7. Normal muscle mass: normal skeletal muscle mass index (SMI), measured by Bioimpedance analysis (BIA, ≥ 10.75 kg/m2).
8. Normal muscle strength: handgrip strength (measured with the Jamar dynamometer) of ≥ 30 kg.

for Sedentary, Pre-frail subjects:

1. Sedentary, pre-frail males. Pre-frailty is defined as fulfilling to at least two out of the following three criteria: low physical performance (low gait speed, i.e. a walking speed below 0.8 m/s in the 4-m walking test), low muscle mass (a low skeletal muscle mass index (SMI), measured by Bioimpedance analysis (BIA, \< 10.75 kg/m2)) and/or low muscle strength: handgrip strength (measured with the Jamar dynamometer) of \< 30 kg. Sedentary behaviour is defined as having an activity category of 1 as assessed by the International Physical Activity Questionnaires (IPAQ) (Activity level is ≥ 600 MET (metabolic equivalent unit) - minutes per week).
2. Body mass index (BMI) between 15 and 32 kg/m2, inclusive.
3. Able to participate and willing to give written informed consent and to comply with the study restrictions.
4. \>61 years of age, inclusive.

Exclusion Criteria

* for Active, Healthy subjects:

1. Presence of any contraindication to have MRI scans performed (e.g. pacemaker, intracranial clips etc.).
2. Having diabetes mellitus or lower extremity peripheral vascular disease, as these conditions may interfere with interpretation of the dynamic 31P-MRS and NIRS of the lower extremity.
3. Participation in a clinical trial within 90 days of screening or more than 4 times in the previous year.
4. A history (within 3 months of screening) of alcohol consumption exceeding 2 standard drinks per day on average (1 standard drink = 10 grams of alcohol).
5. Smoking within 3 months prior to screening and inability to refrain from smoking during the course of the study (from screening to End-of-Study \[EOS\]).
6. A history or presence of allergy to 5-aminolevulinic acid or porphyrins.
7. A history or presence of allergy to lidocaine.
8. Positive hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV Ab), or human immunodeficiency virus antibody (HIV Ab) at screening.
9. Loss or donation of blood over 500 mL within three months (males) or four months (females) prior to screening.
10. Unwillingness or inability to refrain from consuming alcohol within 48 hours before each visit until the end of that visit.
11. Unwillingness or inability to refrain from consuming 8 or more units of xanthine containing beverages and foods per day during the entire study.
12. Unwillingness or inability to refrain from consuming the following supplements: L-carnitine, creatine, Q10, vitamin A, niacin, folic acid, vitamin C, vitamin E and probiotic- foods and supplements at least two weeks before study enrolment.
13. Unwillingness or inability to have a muscle biopsy performed.

For Sedentary, Pre-frail subjects

1. Presence of any contraindication to have MRI scans performed (e.g. pacemaker, intracranial clips etc.).
2. Having diabetes mellitus or lower extremity peripheral vascular disease, as these conditions may interfere with interpretation of the dynamic 31P-MRS and NIRS of the lower extremity.
3. Participation in a clinical trial within 90 days of screening or more than 4 times in the previous year.
4. A history (within 3 months of screening) of alcohol consumption exceeding 2 standard drinks per day on average (1 standard drink = 10 grams of alcohol).
5. Smoking within 3 months prior to screening and inability to refrain from smoking during the course of the study (from screening to EOS).
6. A history or presence of allergy to 5-aminolevulinic acid or porphyrins.
7. A history or presence of allergy to lidocaine.
8. Positive hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV Ab), or human immunodeficiency virus antibody (HIV Ab) at screening.
9. Loss or donation of blood over 500 mL within three months (males) or four months (females) prior to screening.
10. Unwillingness or inability to refrain from consuming alcohol within 48 hours before each visit until the end of that visit.
11. Unwillingness or inability to refrain from consuming 8 or more units of xanthine containing beverages and foods per day during the entire study.
12. Unwillingness or inability to refrain from consuming the following supplements: L-carnitine, creatine, Q10, vitamin A, niacin, folic acid, vitamin C, vitamin E and probiotic- foods and supplements at least two weeks before study enrolment.
13. Unwillingness or inability to have a muscle biopsy performed.
14. Underlying chronic disease, which, in the opinion of the investigator would interfere with study participation or the validity of the measurements.
15. Unintentional weight loss ≤5% of usual body weight during the last 6 months.
16. Anorexia or anorexia-related symptoms

Minimum Eligible Age

61 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes